RxDoctor Payments Data

Jeffrey Pettigrew

Optometrist · Norman, OKNPI 1497894844

Payments from drug & device makers

$2,087in general payments, 2019–2025

Across 146 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Sight Sciences, Inc.$163
  • Optos, Inc.$144
  • Johnson & Johnson Vision Care, Inc.$143
  • Bausch & Lomb Americas Inc.$109
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$73
  • plus $296 from 10 others

What the payments were for

  • Food & beverage$2,02597%
  • Entertainment$623%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,087 in reported general payments places this provider in the 75th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$75,230
Medicare patients
282
Services billed
1,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine17$23,804
LumiganBimatoprost37$15,623
VyzultaLatanoprostene Bunod13$6,655
Loteprednol Etabonate14$1,720
Tobramycin-DexamethasoneTobramycin/Dexamethasone21$753
Latanoprost36$723
Prednisolone Acetate20$617
ErythromycinErythromycin Base13$178
Timolol Maleate12$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$37$39,42754 claims
Bausch & Lomb Americas Inc.Vyzulta$109$6,65513 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$73$1,72014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 714 optometrist providers in Oklahoma.

Other optometrist in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →